Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

Autor:	S. Amet, Gilbert Deray, Nicolas Poulalhon, Morgane Gosselin, Valérie Garrigue, Vincent Launay-Vacher, Thibault Fraisse, Sarah Zimner-Rapuch, Nicolas Janus
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Melanoma Dacarbazine medicine.medical_treatment Renal function Cancer medicine.disease Surgery Targeted therapy Nephrotoxicity Internal medicine medicine Vemurafenib business medicine.drug Kidney disease
Zdroj:	Cancer. 120:2158-2163
ISSN:	0008-543X
Popis:	BACKGROUND Vemurafenib is a BRAF inhibitor that has become the cornerstone of metastatic or inoperable melanoma therapy since its approval in 2011 in the United States and 2012 in Europe. This targeted therapy has shown impressive results in terms of increased progression-free and overall survival as compared to dacarbazine. The safety profile did not include any renal manifestations at that time. METHODS This report is the first case series of 8 patients who experienced significant to severe renal insufficiency under vemurafenib treatment. RESULTS This case series shows that vemurafenib may induce potentially severe acute renal failure, including renal sequelae and persistent kidney disease in some cases. CONCLUSIONS Further studies are needed to investigate the effects of vemurafenib on the kidneys. Meanwhile, renal function should be closely monitored in treated patients for early detection of any renal dysfunction occurrence. Cancer 2014;120:2158–2163. © 2014 American Cancer Society.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cb681863f257d3e1e513bff4d5b9fa0f https://doi.org/10.1002/cncr.28709 Zobrazit plný text záznamu Plný text